- Open Access
Patient-derived xenografts: a relevant preclinical model for drug development
- Luca Pompili†1, 2,
- Manuela Porru†1,
- Carla Caruso2,
- Annamaria Biroccio3 and
- Carlo Leonetti1Email authorView ORCID ID profile
© The Author(s). 2016
- Received: 29 October 2016
- Accepted: 22 November 2016
- Published: 5 December 2016
Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the ‘right’ treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.
- Immunosuppressed mice
- Tumor heterogeneity
- Predictive value
Ever since the first studies reported on the use of in vivo murine leukemia models for drug efficacy in the 1950s , vast efforts have been devoted to the development of animal models in cancer to predict the response of chemotherapeutics in humans. The introduction of a variety of immuno-deficient mice enabled us to engraft tumour cell lines by ectopic or orthotopic injection. While this approach allows many models to be established with relative ease, these xenografts bear little resemblance with the original tumours, in terms of molecular complexity and tumour heterogeneity. It is for these reasons, that the use of these models in evaluating novel agents is limited and can account for the strong discrepancy between preclinical efficacy and clinical response for cancer disease .
In recent years, patient-derived xenografts (PDXs), where tumour fragments from patients are directly implanted in immunodeficient mice and then passed in vivo directly from mouse to mouse, have emerged as important tools for translational research. PDXs maintain the cellular and histological structure of the original tumour and include critical stromal elements, which provide sustenance under periods of extensive growth . Moreover, cytogenetic analysis of tumours from PDXs revealed strong preservation of the overall genomic and gene expression profile of the corresponding patient tumours [4, 5]. Interestingly, the response/resistance of PDXs to standard chemotherapeutics or targeted compounds closely correlated with clinical data in patients from which PDXs had been derived [6, 7]. All these characteristics highlight the use of PDXs as more predictive experimental models for evaluating therapeutic responses.
PDXs are developed by implanting fresh human tumour fragments in immunosuppressed mice. Usually, the time required for the tumour to take is between 2–4 months, although failure of engraftment should not be ascertained until at least 6 months and beyond .
Concerning the tumour engraftment sites, the most common site is the subcutaneous (s.c.) injection of the tumour administered through a small incision made on the dorsal region of the mice. A modification of this classical s.c. procedure has recently been proposed, consisting in the positioning of specimens in a dorsal intramuscular pocket of the mice. The authors reported that in esophageal PDX models this technique produced an improved tumour take-rate (72%) compared to the 17% observed with the standard subcutaneous method , attributing the higher success rate of intramuscular implants to the greater blood supply in the transplant bed. This seems to be a very convincing hypothesis but given the small number of samples evaluated, the effective superiority of this novel implantation technique should be validated in further larger studies and in different tumour histotypes.
The predictive value of PDXs for clinical outcome
Corrispondence with patientsb
Marangoni et al. (ref. 8)
Zhang et al. (ref. 19)
Docetaxel, Doxorubicin, Trastuzumab + Lapatinib
Bertotti et al. (ref. 17)
Ricci et al. (ref. 9)
Topp et al. (ref. 6)
Small cell lung cancer
Anderson et al. (ref. 23)
Nunes et al. (ref. 7)
8/8 responded to Cetuximab
Bertotti et al. (ref. 17)
KRAS mutated (18/85)
18/18 not responded to Cetuximab
Non-small cell lung cancer
Zhang et al. (ref.12)
EGFR mutated (1/10)
1/10 responded to Gefitinib
The study by Bertotti et al.  performed on a very large cohort of PDXs obtained from metastatic colorectal cancer, strongly supports the role of this model in mimicking the response of this disease in humans. In fact, they showed that, when unselected PDXs were treated with Cetuximab, the percentage rate regarding response (about 11%), disease stabilization (30%) and progression (59%) was in line with the data reported in the retrospective analysis of the unselected patients treated with Cetuximab or Panitumumab.
The need for better, more clinically predictive models of epithelial ovarian cancer which account for 90% of ovarian cancer, led Giavazzi’s group  to develop a panel of 34 PDOXs that recapitulated molecular and biological characteristics of this lethal malignancy. The established xenografts were histologically similar to the patient tumours and resembled the five main subtypes of epithelial ovarian cancer such as high-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma and low-grade serous carcinoma. Moreover, when engrafted intraperitoneally, xenografts reproduced the ability of human ovarian cancer to disseminate. They reported that in most PDOXs, the response to the treatment with Cisplatin matched with the corresponding patients. The paper by Topp et al.  confirms that ovarian cancer PDXs not only retain the phenotypic and molecular characteristics of original tumours but also resemble the clinical response to Cisplatin. In fact, the sensitivity or resistance observed in patients was consistent with the experimental data in corresponding PDXs. Interestingly, when mice bearing recurrent tumours were re-treated with a 2nd and a 3rd-line treatment, an increased resistance to Cisplatin was observed as in the clinical setting following subsequent cycle of therapy, thus confirming that this model reflects the clinical situation and could also be a very useful tool in studying the mechanisms of tumour resistance. Finally, a good correlation between the response rate to chemotherapy with Cisplatin and Etoposide combination, the approved therapeutic regimen for Small Cell Lung Cancer (SCLC), between SCLC patients and PDXs to chemotherapy, has also been reported. In particular, the authors reported only one exception to this concordance, as one PDX was resistant to the treatment, while the patient from which this PDX was derived, elicited a good response. They hypothesized that these differences could be due to establishing a more aggressive clone in mice or that additional mutations may have occured during the growth of the PDXs .
In the search for effective therapies for unresectable gastric cancer, experiments performed on PDXs deriving from 8 patients demonstrated that Regorafenib, a multikinase inhibitor with activity against a range of protein kinases involved in oncogenesis (KIT, RET, and RAF), angiogenesis (VEGFR1–3 and TIE2), and maintenance of the tumour microenvironment (PDGFR and FGFR), was very active in reducing the growth of tumours in mice. Looking at the mechanisms involved in the antitumoral activity of these compounds, the authors reported a reduction in angiogenesis and proliferation associated with apoptosis induction . Interestingly, these results are consistent with a recent phase II trial in patients with refractory advanced gastric cancer (INTEGRATE) , as a significantly longer progression-free survival was observed in the Regorafenib group versus placebo.
Notably, PDXs could also be useful models for identifying predictive biomarkers of response to targeted therapies. For example, recently published studies on colon cancer PDXs confirm clinical data regarding the key role of WT KRAS genotype for the clinical efficacy of anti-EGFR therapy. In fact, while WT KRAS PDXs were sensitive to Cetuximab treatment , PDXs bearing KRAS mutations were unresponsive to the treatment  and these observations were concordant with the retrospective analysis in the matched patients.
The utility of PDXs in supporting a precise selection of patients for EGFR-targeted therapies such as Gefitinib has also been demonstrated . These authors selected 10 PDXs from Non-Small Cell Lung Cancer (NSCLC) patient specimens and treated mice with the EGFR tyrosine kinase Gefitinib, which is known to be active in patients with NSCLC. They observed that the only one PDX model with EGFR Exon19 Del. activating mutation responded completely to Gefitinib, while PDXs with KRAS mutations or EGFR wild-types were insensitive to Gefitinib treatment. Even though the authors were not able to report response to Gefitinib in matched patients, these results are consistent with that reported in clinical trials , thus validating once again that PDX models represent powerful tools in predicting the response to anticancer therapy.
Evidence showing that PDXs have a high predictive power for the efficacy of standard and novel anticancer therapeutics has encouraged the idea to employ this platform in the so-called co-clinical trials, where in vivo preclinical studies and clinical trials could be performed in parallel, with the aim to specifically target the unique cancer of a patient or subgroup of patients. In particular, the concept of co-clinical trials refers to studies capable of defining a patient selection strategy based on molecular abnormalities or identifying mechanisms of resistance to antitumoral therapies, for the development of precision medicine aimed at personalizing anticancer treatment. In this context, PDXs could be also used as an ‘avatar’ model, in which PDXs obtained from a patient enrolled in a clinical trial could be treated with the same therapy administered to the patient, thus permitting to identify biomarkers of sensitivity or resistance to treatments.
Most intriguingly, since a major cause of failure of treatments is the acquired resistance of tumours , the use of novel drugs or combination could permit to select effective therapeutic strategies for second-line treatment. On this basis, Misale et al.  started patients with colorectal cancer on treatment with anti-EGFR inhibitors as single agents after initial response elicited relapse of the disease, due to emerging resistance. Thus, by using colon cancer PDX as a model, they investigated how the acquisition of resistance to EGFR-targeted therapies could be restrained. The in vitro genetic screen and functional studies on CRC showed that dual blockade of EGFR and MEK prevents acquired resistance and as a result performed experiments in vivo on PDXs derived from a CRC patient carrying a quadruple wild-type gene profile (KRAS, NRAS, BRAF and PIK3CA) which recapitulate the molecular profile of patients sensitive to anti-EGFR antibodies. Treatment of PDXs with the anti MEK Pimasertib alone only slightly reduced tumour growth, while Cetuximab treatment was very effective in reducing tumours to more than 70%. The subsequent regrowth of these tumours, showed resistance to drug re-challenge thus resembling the clinical findings. In contrast, the Cetuximab/Pimasertib combination elicited a complete response as tumours remained undetectable for more than 6 months. These results led authors to suggest that the use of ‘ab initio’ combination treatment could inhibit the development of resistant tumours showing molecular heterogeneity as well as highlight the usefulness of PDXs in establishing a very effective antitumoral strategy.
To search for a second-line personalized treatment in melanoma patients acquiring resistance to BRAF inhibitors, Krepler et al.  established 12 PDX models from–progressed patients of which 3 with NRAS mutations, MAP2K1 (MEK1) mutations in 2, BRAF amplification in 4, and aberrant PTEN in 7. Moreover, amplification of MET was observed in 3 PDXs, while re-activation of phospho-MAPK predominated at the protein level, with parallel activation of PI3K in a subset of PDXs. Treating mice with a combination of compounds acting on the different resistance mechanisms produced a marked antitumor efficacy. In particular, the triple combination treatment with Capmatinib/Encorafenib/Binimetinib, targeting MET, MAPK and PI3K pathways resulted to be more effective. This strategy which uses a different cohort of mice deriving from the same patients and bearing the same targetable mechanism of resistance, makes it possible to identify an accurate personalized therapy regimen, thus avoiding treatment failures.
A paradigmatic example of the use of PDX as an “avatar” for personalized cancer treatment is reported by Bousquet et al. . In particular, a woman with a localized left breast ductal invasive triple-negative breast carcinoma treated with chemotherapy and radiation, in accordance with French national guidelines, elicited a disease relapse. PDXs obtained from metastatic nodules were analyzed by transcriptome analysis and treated with different drug combinations, resulting Paclitaxel plus Cetuximab as the most efficient therapy. Following these results in PDXs, the patient was treated with Paclitaxel plus Cetuximab and after 3 months of this second-line treatment, the metabolic response was almost complete. Moreover, the time to progression was longer than previous lines of treatment.
These examples demonstrate that PDX models integrated with targeted sequencing and phosphoproteomic platforms, provide the preclinical basis for identifying more effective therapies both in the first and second-line targeted inhibitor strategies, also for the repositioning and/or repurposing of previously approved drugs.
Although PDXs possess notable advantages compared to classical xenografts as described above, they do have some limitations that cannot be omitted. Importantly, overcoming these issues could increase this model’s potential for improving therapeutic application of antineoplastic compounds.
One of the major limitations of PDXs is that tumours fail to progress or to metastasize and therefore do not retain all patterns of the disease course observed in patients. One strategy to overcome this disadvantage is represented by the engraftment of tumour specimens in the orthotopic sites of origin. To this purpose, several reports have shown that patient-derived orthotopic xenografts (PDOXs) could represent a powerful tool for addressing this key point in the science of preclinical modelling. Particularly, DeRose et al.  reported that the establishment of breast tumours into the mammary glands of mice maintain clinical features of original tumours as the majority of mice developed metastases corresponding to patient metastatic sites, such as lymph nodes, lungs, bone and peritoneum. Moreover, Walters et al.  showed that PDOXs of pancreatic carcinoma developed peritoneal and liver metastasis, thus recapitulating the clinical aspects of human disease. The relevance of using PDOX in evaluating an anti- metastatic therapy is highlighted by Hiroshima et al.  in a model of HER2-positive cervical cancer showing peritoneal dissemination, liver, lung and lymph node metastasis. In particular, these authors observed a different sensitivity to chemotherapy between primary tumor and metastasis. In fact, while the subcutaneous model and the primary tumor of PDOX from the same tumor were not sensitive to Entinostat, a benzamide histone deactylase inhibitor, Entinostat-treatment reduced significantly the size of metastasis in comparison to mice treated with the vehicle.
At the same time the s.c. implantation does not represent the site of origin, thus limiting studies on evaluating the role of the tumour microenvironment as it is well known that the cells of the tumour vasculature, fibroblasts and inflammatory cells, interacting with tumour cells, are important in tumour biology and that the microenvironment regulates cancer-drug sensitivity . Thus, the orthotopic implanting fragments directly into the organ of origin (PDOXs), requiring very skilled personnel, better recapitulates the complexity of human malignancy  and should be extensively adopted. In this regard, advanced real-time imaging systems permit the quantitative assessment of primary tumour growth and metastatic progression, relying on the use of imaging modalities. In relation to this, Fluorodeoxyglucose–positron emission tomography (FDG-PET) has been proposed and the feasibility of this technique has been confirmed by magnetic resonance [34, 35]. Furthermore, based on the observation that more than 90% of pancreatic cancers are EGFR-positive, a novel imaging approach which combines micro PET and F(ab’)2 fragments of the fully-human anti-EGFR monoclonal antibody, panitumumab has been evaluated . The authors demonstrated that 64Cu-panitumumab F(ab’)2 fragments bound with high affinity to EGFR on PDOXs pancreatic cancer, allowed to visualize the tumour by microPET/CT. They suggest that this method could also be useful for tumour imaging in patients and for radioimmunotherapy. Finally, the use of fluorescently-labelled chimeric anti-CEA antibody permitted whole body imaging of colon cancer PDOXs. To this purpose, tumour mice bearing were injected with the anti-CEA antibody labelled with the AlexaFluor 488 and then seen by a small animal imaging system that was able to detect the primary tumour and the residual mass after the surgical resection .
A further limitation of the model is that mice used for engraftment have a severely compromised immune system which poses a disadvantage for the full exploitation of PDX technology, since the contribution of immune-cell function hinders the proper evaluation of tumour growth and patient response in these models. This is particularly true in certain tumours such as melanoma in which progresses in treating this neoplasia have been made with targeted immunotherapy [38, 39]. The use of the so-called humanized mice with co-engrafted stromal and immune components, will allow researchers to study tumour growth and drug response in the context of human immunosystem which could represent the most advanced preclinical models for drug efficacy studies with some aspects needing improvement .
One critical aspect concerns the maintenance of PDXs in the genetic integrity of parental tumours and the degree of alterations occurring across the passages into new mice. To this purpose there are many examples throughout literature reporting that in the initial passages, PDXs retain the histological, immunohistochemistry, gene expression, copy numbers and chromosomal stability profile of the original patient tumour [3, 4]. Modifications of tumour characteristics occurring during passages could influence the response to chemotherapy. It was for this purpose that in a recent paper, Dodbiba et al.  evaluated whether chemosensitivity could be modified through the passages in mice. PDXs were treated with combination treatments including Cisplatin, Paclitaxel and 5-Fluorouracil which are drugs used for the clinical management of esophageal and gastro-esophageal junction cancer. The authors observed that the inherent resistance, gain-of-resistance or chemosensitivity remained generally constant across 3 to 11 passages in mice.
In contrast, genetic changes that occurred via each passage to a new mouse host seem to represent genomic rearrangements intrinsic to tumour progression. In particular, in breast cancer PDXs it was observed that tumours in mice showed a pronounced mutational status or aggressiveness of tumour characteristics, sometimes comparable to patient metastases compared to primary tumours . These observations suggest the use of PDX models with low passage numbers (<10) to preserve the genetic integrity of the parental tumour .
Perhaps one major obstacle in PDX modelling for co-clinical trials and personalized medicine is the long timeframe required for engraftment. In fact, the tumour latency calculated as the time between implantation and the development of a progressively growing xenograft tumour can range from 2 to 12 months. Considering that tumours have to be passaged several times in mice to generate a sufficient number of “avatars”, this means that individual patients with a rapidly progressing disease could not benefit from PDX studies. To this purpose, performing drug testing in PDXs during the period of standard therapy could be a useful strategy in view of the second-line treatment based on PDXs results.
PDX models are a relevant preclinical platform and represent a significant challenge for oncology research as they, more accurately, reflect human tumour biology than any other existing models. If PDXs are viewed as complementary to other experimental models, the use of PDXs should lead to a higher rate of success in identifying new and more effective therapeutic strategies and in transitioning into individualized therapy. The aforementioned limitations of this model, the high costs associated with maintaining mouse colonies and regulatory issues have hindered the full exploitation and widespread utilization of this methodology, therefore vast efforts are needed to refine the model and overcome these challenges. The collaboration between private and public institutes devoted in the fight against cancer, in developing and characterizing large collections of PDX models from different cancer types, will accelerate progress in the area of drug development. In conclusion, the long-term benefits of using more relevant preclinical models of human tumour biology merit these efforts and expenses.
We are grateful to Dr. Adele Petricca for secretarial assistance and to Tania Merlino for the English revision.
This work was supported by grants from Italian Association for Cancer Research AIRC IG 14337 (CL) and AIRC IG 16910 (AB). Footnotes.
Availability of data and material
Please contact the corresponding author.
LP, MP performed experiments and analyzed data. CC, AB and CL contributed to the writing of the manuscript. All the authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
All animal procedures were approved by the ethics committee of the Regina Elena National Cancer Institute (CE/534/12 and CE/823/16) and were in compliance with the national (D.L. March 4, 2014, no. 26) and european directives (directive 2010/63/EU of the European Parliament and of the council).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Kirschbaum A, Geisse NC, Sister TJ, Meyer LM. Effect of certain folic acid antagonists on transplanted myeloid and lymphoid leukemias of the F strain of mice. Cancer Res. 1950;10:762–8.PubMedGoogle Scholar
- Hutchinson L, Kirk R. High drug attrition rates-where are we going wrong? Nat Rev Clin Oncol. 2011;8:189–90.View ArticlePubMedGoogle Scholar
- Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.View ArticlePubMedPubMed CentralGoogle Scholar
- Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012;14:R11.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao X1, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol. 2012;14:574–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol. 2014;8:656–68.View ArticlePubMedPubMed CentralGoogle Scholar
- Nunes M, Vrignaud P, Vacher S, Richon S, Lievre A, Cacheux W, et al. Evaluating patient-derived colorectal cancer-xenografts as preclinical models by comparison with patient clinical data. Cancer Res. 2015;75:1560–6.View ArticlePubMedGoogle Scholar
- Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13:3989–98.View ArticlePubMedGoogle Scholar
- Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 2014;74:6980–90.View ArticlePubMedGoogle Scholar
- Russell PJ1, Russell P, Rudduck C, Tse BW, Williams ED, Raghavan D. Establishing prostate cancer patient derived xenografts: lessons learned from older studies. Prostate. 2015;75:628–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14:6456–68.View ArticlePubMedGoogle Scholar
- Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med. 2013;11:168.View ArticlePubMedPubMed CentralGoogle Scholar
- John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res. 2011;17:134–41.View ArticlePubMedGoogle Scholar
- DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17:1514–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Némati F1, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res. 2010;16:2352–62.View ArticlePubMedGoogle Scholar
- Klinghammer K1, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, et al. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option. Int J Cancer. 2015;136:2940–8.View ArticlePubMedGoogle Scholar
- Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508–23.View ArticlePubMedGoogle Scholar
- Bernardo C, Costa C, Sousa N, Amado F, Santos L. Patient-derived bladder cancer xenografts: a systematic review. Transl Res. 2015;166:324–31.View ArticlePubMedGoogle Scholar
- Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73:4885–97.View ArticlePubMedPubMed CentralGoogle Scholar
- Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013.View ArticlePubMedPubMed CentralGoogle Scholar
- Read M, Liu D, Duong CP, Cullinane C, Murray WK, Fennell CM, et al. Intramuscular transplantation improves engraftment rates for esophageal patient-derived tumor xenografts. Ann Surg Oncol. 2016;23:305–11.View ArticlePubMedGoogle Scholar
- Anderson WC, Boyd MB, Aguilar J, Pickell B, Laysang A, Pysz MA, et al. Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. PLoS One. 2015;10:e0125255.View ArticlePubMedPubMed CentralGoogle Scholar
- Huynh H, Ong R, Zopf D. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. J Exp Clin Cancer Res. 2015;34:132. doi:10.1186/s13046-015-0243-5.View ArticlePubMedPubMed CentralGoogle Scholar
- Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein DJ. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. Clin Oncol. 2016;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901.
- Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncolol. 2009;2:2.View ArticleGoogle Scholar
- Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira P, Urabayashi MS, Martens AA, Neves JH, Machado-Santelli GM. The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res. 2014;33:37. doi:10.1186/1756-9966-33-37.View ArticlePubMedPubMed CentralGoogle Scholar
- Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun. 2015;6:8305.View ArticlePubMedPubMed CentralGoogle Scholar
- Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, et al. Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies. Clin Cancer Res. 2016;22:1592–602.View ArticlePubMedGoogle Scholar
- Bousquet G, Feugeas JP, Ferreira I, Vercellino L, Jourdan N, Bertheau P, et al. Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma. Breast Cancer Res. 2014;16:401.View ArticlePubMedPubMed CentralGoogle Scholar
- Walters DM, Stokes JB, Adair SJ, Stelow EB, Borgman CA, Lowrey BT, et al. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PLoS One. 2013;8:e77065.View ArticlePubMedPubMed CentralGoogle Scholar
- Hiroshima Y, Maawy A, Zhang Y, Zhang N, Murakami T, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Endo I, Hoffman RM. Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy. Oncotarget. 2016 Sep 28. doi: 10.18632/oncotarget.12322. [Epub ahead of print]Google Scholar
- Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med. 2012;18:1332–4.View ArticlePubMedGoogle Scholar
- Yano S, Hiroshima Y, Maawy A, Kishimoto H, Suetsugu A, Miwa S, et al. Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery. Cancer Gene Ther. 2015;22:344–50.View ArticlePubMedPubMed CentralGoogle Scholar
- Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and Geno- and phenotypes of patient tumours. Int J Cancer. 2015;136:E252–61.View ArticlePubMedGoogle Scholar
- Sicklick JK, Leonard SY, Babicky ML, Tang CM, Mose ES, French RP, et al. Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. J Transl Med. 2014;12:41.View ArticlePubMedPubMed CentralGoogle Scholar
- Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab’)2 fragments. Nucl Med Biol. 2015;42:71–7.View ArticlePubMedGoogle Scholar
- Hiroshima Y, Maawy A, Sato S, Murakami T, Uehara F, Miwa S, et al. Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery ofpatient and cell-line pancreatic tumors growing orthotopically in nude mice. J Surg Res. 2014;187:510–7.View ArticlePubMedGoogle Scholar
- Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273–90.View ArticlePubMedGoogle Scholar
- Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res. 2014;33:30. doi:10.1186/1756-9966-33-30.View ArticlePubMedPubMed CentralGoogle Scholar
- Morton JJ, Bird G, Refaeli Y, Jimeno A. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. Cancer Res. 2016;76(21):6153-6158.Google Scholar
- Dodbiba L, Teichman J, Fleet A, Thai H, Starmans MH, Navab R, et al. Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. PLoS One. 2015;10:e0121872.View ArticlePubMedPubMed CentralGoogle Scholar
- Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73:5315–9.View ArticlePubMedPubMed CentralGoogle Scholar